JP2013500739A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500739A5
JP2013500739A5 JP2012523432A JP2012523432A JP2013500739A5 JP 2013500739 A5 JP2013500739 A5 JP 2013500739A5 JP 2012523432 A JP2012523432 A JP 2012523432A JP 2012523432 A JP2012523432 A JP 2012523432A JP 2013500739 A5 JP2013500739 A5 JP 2013500739A5
Authority
JP
Japan
Prior art keywords
polypeptide
nucleic acid
antibody
disease
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500739A (ja
Filing date
Publication date
Priority claimed from IL200202A external-priority patent/IL200202A0/en
Application filed filed Critical
Publication of JP2013500739A publication Critical patent/JP2013500739A/ja
Publication of JP2013500739A5 publication Critical patent/JP2013500739A5/ja
Pending legal-status Critical Current

Links

JP2012523432A 2009-08-02 2010-08-02 新規タンパク質 Pending JP2013500739A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL200202 2009-08-02
IL200202A IL200202A0 (en) 2009-08-02 2009-08-02 Novel proteins
PCT/IL2010/000621 WO2011016026A2 (en) 2009-08-02 2010-08-02 Novel proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015047903A Division JP5833780B2 (ja) 2009-08-02 2015-03-11 新規タンパク質
JP2015155720A Division JP2015212302A (ja) 2009-08-02 2015-08-06 新規タンパク質

Publications (2)

Publication Number Publication Date
JP2013500739A JP2013500739A (ja) 2013-01-10
JP2013500739A5 true JP2013500739A5 (enExample) 2013-09-12

Family

ID=42263570

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012523432A Pending JP2013500739A (ja) 2009-08-02 2010-08-02 新規タンパク質
JP2015047903A Expired - Fee Related JP5833780B2 (ja) 2009-08-02 2015-03-11 新規タンパク質
JP2015155720A Pending JP2015212302A (ja) 2009-08-02 2015-08-06 新規タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015047903A Expired - Fee Related JP5833780B2 (ja) 2009-08-02 2015-03-11 新規タンパク質
JP2015155720A Pending JP2015212302A (ja) 2009-08-02 2015-08-06 新規タンパク質

Country Status (11)

Country Link
US (1) US8647632B2 (enExample)
EP (2) EP2461829B1 (enExample)
JP (3) JP2013500739A (enExample)
KR (1) KR101623355B1 (enExample)
CN (1) CN102596247B (enExample)
AU (1) AU2010280368B2 (enExample)
CA (1) CA2769001C (enExample)
IL (3) IL200202A0 (enExample)
IN (1) IN2012DN00879A (enExample)
SG (2) SG10201404735VA (enExample)
WO (1) WO2011016026A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742061A4 (en) * 2011-08-08 2015-05-27 Two To Biotech Ltd NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND USES THEREOF IN METHODS FOR THE TREATMENT OF METABOLIC, CARDIAC AND IMMUNE DISORDERS
SG11201605354WA (en) * 2014-01-02 2016-07-28 Two To Biotech Ltd Novel polypeptides
CN104262468B (zh) * 2014-09-28 2017-01-18 新乡医学院 一种葡萄糖转运蛋白抑制多肽及其制备方法、应用
ES2746157T3 (es) 2015-03-05 2020-03-04 Sekisui Specialty Chemicals Am Dispersante de PVOH para polimerización de VCM
US11427872B2 (en) 2015-12-11 2022-08-30 National University Corporation Kochi University Marker for pancreatic cancer and intraductal papillary mucinous neoplasms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5286846A (en) 1991-06-14 1994-02-15 The Government Of The United States Of America As Represented By The Dept. Of Health And Human Services Amino acid derivative and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
WO2001087316A2 (en) * 2000-05-15 2001-11-22 Braswell, Glenn, A. Composition and method for increasing testosterone levels
EP1296706B1 (en) * 2000-06-19 2006-02-22 The Uab Research Foundation Osteoclast secreted chemokine and uses thereof
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20080206231A1 (en) * 2004-10-05 2008-08-28 Oregon Health And Science University Compositions and Methods for Treating Disease
US20080248134A1 (en) * 2005-05-04 2008-10-09 Auckland Uniservices Limited Oral compositions, use and combinations of N-[2-(dimethylamino)ethyl]-2,6 dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide and closely related analogues thereof
US20090018031A1 (en) * 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods

Similar Documents

Publication Publication Date Title
Liu et al. The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis
AU2014317035B2 (en) IL-18 binding protein (IL-18BP) in inflammatory diseases
US12173055B2 (en) N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
Cavone et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophil cell death
US20090253632A1 (en) Therapeutic peptides and method
CN106164675B (zh) 检测人类骨膜蛋白的新型测定
EP3076985B1 (en) Composition comprising probiotics overexpressing clpb protein for use in the treatment of obesity
JP2013500739A5 (enExample)
KR20230116850A (ko) Trem2 작용제 바이오마커 및 이의 사용 방법
EP2838559B1 (en) Combination therapy of anti-mif antibodies and glucocorticoids
AU2024284360A1 (en) Tnf inhibitor combination therapies
WO2014165866A2 (en) Methods for immune-based diagnosis, prevention and personalized treatment of narcolepsy
EP4310099A1 (en) Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis
WO2021021830A1 (en) Antibodies to candida and uses thereof
CN102307894B (zh) 螨过敏原之变体及其用途
KR20170098941A (ko) 인간 dpp-4를 검출하기 위한 검정법
CN119390843B (zh) 抗tl1a抗体及其制备方法和应用
WO2014181273A1 (en) Methods for treating inflammatory bowel disease
Yu et al. TFEB SUMOylation in Airway Epithelial Cells Impairs Lysosomal Biogenesis to Promote Asthma Development
US7754207B2 (en) Methods of treating pulmonary fibrosis
CN117425672A (zh) 用于改善急性肺损伤和肺纤维化急性加重的药物组合物
US20230416381A1 (en) Methods for treating or preventing acute respiratory distress syndrome
Zheng et al. Clinical and genetic characteristics in maternally inherited diabetes and deafness (MIDD) with mitochondrial m. 3243A> G mutation: A 10-year follow up observation study of 1 family
EP4573121A1 (en) Method of selecting patients for treatment with an il-33 axis antagonist
Qi et al. The involvement of proline-rich protein Mus musculus predicted gene 4736 in ocular surface functions